InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: wcopeland post# 960

Saturday, 05/20/2017 4:48:33 PM

Saturday, May 20, 2017 4:48:33 PM

Post# of 2099
Exactly. I feel the same way.

By the way, if/when VB-111 gets marketed, this comment gives you an idea of how it'll be priced:

“It will not be a very cheap drug,” Erez Feige, the company’s VP of business operations, said in an interview, adding that “we believe it should be in the range of” Merck’s Keytruda, which rings up at $150,000 per year. But “if the drug is really improving overall survival,” he said, “there’s justification to pay for that.”

http://www.fiercepharma.com/pharma/no-scandal-here-say-rare-disease-drugmakers-as-pricing-scrutiny-lands-their-doorstep
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News